(Q36619788)

English

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.

scientific article published on October 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

12

object named as

Linch DC

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Anthony H. Goldstone

5

object named as

Goldstone AH

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Harrison CN

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Gregory W

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Hudson GV

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Devereux S

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Hancock B

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Winfield D

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

MacMillan AK

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Hoskin P

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Newland AC

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Milligan D

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 October 1999

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

81

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

476-483

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

30 September 2017

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

30 September 2017

Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

30 September 2017

Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

30 September 2017

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

30 September 2017

Therapy associated leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

30 September 2017

Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

30 September 2017

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

30 September 2017

Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

28 June 2018

Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

28 June 2018

Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

28 June 2018

Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

28 June 2018

Adjusting survival curves for imbalances in prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

28 June 2018

Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362916

28 June 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

Demonstration of developing myelodysplasia/acute myeloid leukaemia in haematologically normal patients after high-dose chemotherapy and autologous bone marrow transplantation using X-chromosome inactivation patterns

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

LEUKEMIA AND HODGKIN'S DISEASE

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

Risk of second cancers after treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690718

21 January 2018

The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10507773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress

1 reference

https://pubmed.ncbi.nlm.nih.gov/10507773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/10507773

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6690718

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36619788&oldid=2199102855"